Themis Medicare Limited

THEMISMED

INE083B01024

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:51 31/05/2024 BST			5-day change	1st Jan Change
202.8 ^INR	-1.60%		-4.94%	-4.74%

05-14	Themis Medicare Limited Recommends Dividend for Financial Year Ended March 31, 2024, Payable on or after July 22, 2024	CI
05-14	Themis Medicare Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Themis Medicare Limited Announces Resignation of Jayshree Dinesh Patel as Whole-Time Director

March 28, 2022 at 08:13 am

Themis Medicare Limited announced that the present tenure of Mrs. Jayshree Dinesh Patel, Whole Time Director ends on March 27, 2022 and had stepped down from the office of Director with effect from closure of business hours on March 27, 2022.

Latest news about Themis Medicare Limited

Themis Medicare Limited Recommends Dividend for Financial Year Ended March 31, 2024, Payable on or after July 22, 2024	05-14	CI
Themis Medicare Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-14	CI
Themis Medicare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-14	CI
Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-10	CI
Themis Medicare Limited Launches REMITHEM	11-10	CI
Themis Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-04	CI
Themis Medicare Limited Announces Incorporation of Wholly Owned Subsidiary	20/09/23	CI
Themis Medicare Limited Announces Cessation of Vijay Agarwal as Independent Director	09/09/23	CI
Themis Medicare Limited Appoints Reena Patel as Alternate Non-Executive Non- Non-Independent Director to Dr. Adam Demeter, Effective September 11, 2023	07/09/23	CI
Themis Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	10/08/23	CI
Themis Medicare Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	13/05/23	CI
Themis Medicare Limited Reports Earnings Results for the Full Year Ended March 31, 2023	13/05/23	CI
Themis Medicare Limited Recommends Dividend for Financial Year Ended 31 March 2023	13/05/23	CI
Themis Medicare Limited Announces Board Resignations	02/05/23	CI
Themis Medicare Gets Drug Controller General of India’s No-Objection for Diclofenac Injection	17/02/23	MT
Themis Medicare Announces DCGI Approval of Remifentanil Hydrochloride 1mg/2mg for Injection for Import and Marketing	17/02/23	CI
Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	03/02/23	CI
Themis Medicare Launches Drug for Treatment of Menopausal Symptoms in India	04/01/23	MT
Themis Medicare Ltd. Launches Lenzetto Â¡Global Brand of Estradiol Novel Drug Delivery System	03/01/23	CI
Themis Medicare Posts Decline in Fiscal Q2 Consolidated Profit	09/11/22	MT
Themis Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	07/11/22	CI
Themis Medicare Limited entered into share purchase agreement to acquire additional 6.47% stake in Gujarat Themis Biosyn Limited from Pharmaceutical Business Group Limited for approximately INR 700 million.	06/11/22	CI
Themis Medicare Partners with NFL Biosciences to Develop Anti-Smoking Drug in India	07/10/22	MT
NFL Biosciences Partners with Themis Medicare for the Development of NFL-101 in India	05/10/22	CI
Themis Medicare Limited Informs the Second Term of Office of Mr. Hoshang Sinor as Independent Director, Come to End	20/09/22	CI

Chart Themis Medicare Limited

Duration

Period

More charts

Company Profile

Themis Medicare Limited is a research-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. The Company specializes in manufacturing a range of products for application areas like pain management, critical care and anti-infectives. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more.

Sector

Pharmaceuticals

Calendar

11/07/2024 - Ex-dividend day for final dividend

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
THEMIS MEDICARE LIMITED	-4.74%	224M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B